Our company has been listed in the "Japanese Life Science Startup List" edited and managed by the Japan Bioindustry Association and NPO Kinki Bio-Industry Development Organization.New!!
We are pleased to announce that our company has been listed in the "Japanese Life Science Startup List," jointly created and managed by the Japan Bioindustry Association and NPO Kinki Bio-Industry Development Organization. Click here for the list.
Our President, Dr Sugo, will be a lecturer at the webinar 'Fundamentals of genome editing technology and key points for its use in drug discovery research' organised by Research and Development Support Center CO.,LTD.
We are pleased to inform you that Dr Sugo, our company's president, will be a lecturer at the above web-only seminar (date and time: 12 June 2024 (Wed), 13:00-16:00), organised by Research and Development Support Center CO., LTD. Click here for more details of the lecture and registration for the seminar.
Our business was introduced in ThermoFisher Scientific's life science magazine "NEXT" No.67.
We are pleased to inform you that Thermo Fisher Scientific's life science magazine "NEXT" No.67, digitally published on October 25, 2023, features an introduction to our business titled "Diversified development of contract services and collaborative research with our unique genome editing and nucleic acid delivery technologies" Click here for the digital issue in Japanese.
Our President Dr. Sugo's review article is published in the October issue of Hokuryukan's "BIO Clinica" in Japanese.
His review "Propriety Nucleic Acid Delivery Technologies for Realizing a New Therapeutic Modality" is one of the topics for "Research and development of disease therapies using iPS cells" in the October issue published on September 25th, 2023. Click here for the summary of the review in English.
Notice about Decision of a Patent Grant
GenAhead Bio Inc. has been granted a patent for nucleic acid delivery technology in Japan. Click here for the press release
GenAhead Bio licenses CRISPR/Cas9 from Broad Institute
GenAhead Bio Incorporated ("GenAhead") announced today the signing of a non-exclusive commercial research tool and services license agreement to CRISPR / Cas9 genome editing technology from the Broad Institute of MIT and Harvard. GenAhead began operations in 2018 as a spin-out from Takeda Pharmaceutical Company Limited and has since leveraged the latest CRISPR / Cas9 […]
Our highly efficient genome editing technology, CRISPR-SNIPER, was featured in the following article in "Bioradiations"
Our highly efficient genome editing technology, CRISPR-SNIPER, was featured in the following article in "Bioradiations". Title of the article: “Modernizing Gene Editing Detection with Droplet Digital PCR”